Association of systolic and diastolic blood pressure and all cause mortality in people with newly diagnosed type 2 diabetes: retrospective cohort study

Eszter Panna Vamos, Matthew Harris, Christopher Millett, Utz J Pape, Kamlesh Khunti, Vasa Curcin, Mariam Molokhia, Azeem Majeed, Eszter Panna Vamos, Matthew Harris, Christopher Millett, Utz J Pape, Kamlesh Khunti, Vasa Curcin, Mariam Molokhia, Azeem Majeed

Abstract

Objective: To examine the effect of systolic and diastolic blood pressure achieved in the first year of treatment on all cause mortality in patients newly diagnosed with type 2 diabetes, with and without established cardiovascular disease.

Design: Retrospective cohort study.

Setting: United Kingdom General Practice Research Database, between 1990 and 2005.

Participants: 126,092 adult patients (age ≥ 18 years) with a new diagnosis of type 2 diabetes who had been registered with participating practices for at least 12 months.

Main outcome measure: All cause mortality.

Results: Before diagnosis, 12,379 (9.8%) patients had established cardiovascular disease (myocardial infarction or stroke). During a median follow-up of 3.5 years, we recorded 25,495 (20.2%) deaths. In people with cardiovascular disease, tight control of systolic (<130 mm Hg) and diastolic (<80 mm Hg) blood pressure was not associated with improved survival, after adjustment for baseline characteristics (age at diagnosis, sex, practice level clustering, deprivation score, body mass index, smoking, HbA(1c) and cholesterol levels, and blood pressure). Low blood pressure was also associated with an increased risk of all cause mortality. Compared with patients who received usual control of systolic blood pressure (130-139 mm Hg), the hazard ratio of all cause mortality was 2.79 (95% confidence interval 1.74 to 4.48, P<0.001) for systolic blood pressure at 110 mm Hg. Compared with patients who received usual control of diastolic blood pressure (80-84 mm Hg), the hazard ratios were 1.32 (1.02 to 1.78, P=0.04) and 1.89 (1.40 to 2.56, P<0.001) for diastolic blood pressures at 70-74 mm Hg and lower than 70 mm Hg, respectively. Similar associations were found in people without cardiovascular disease. Subgroup analyses of people diagnosed with hypertension and who received treatment for hypertension confirmed initial findings.

Conclusion: Blood pressure below 130/80 mm Hg was not associated with reduced risk of all cause mortality in patients with newly diagnosed diabetes, with or without known cardiovascular disease. Low blood pressure, particularly below 110/75 mm Hg, was associated with an increased risk for poor outcomes.

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: support from the European Community Seventh Framework Programme for the submitted work; CM is funded by the Higher Education Funding Council for England and the NIHR; EV and MH are partly funded by the NIHR; no other relationships or activities that could appear to have influenced the submitted work.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4790717/bin/vame004878.f1_default.jpg
Fig 1 Adjusted risk of all cause mortality in study participants, according to blood pressure level. Cox proportional hazard regression models adjusted for age at diagnosis, sex, practice level clustering, deprivation score, body mass index, smoking, baseline levels of HbA1c and cholesterol, and blood pressure at baseline.
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4790717/bin/vame004878.f2_default.jpg
Fig 2 Kaplan-Meier survival estimates for all cause mortality in study participants with and without cardiovascular disease, according to levels of systolic (SBP) and diastolic (DBP) blood pressure
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4790717/bin/vame004878.f3_default.jpg
Fig 3 Kaplan-Meier survival estimates for all cause mortality according to blood pressure levels in study participants

References

    1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
    1. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009;27:923-34.
    1. Standards of medical care in diabetes—2010. Diabetes Care 2010;33(suppl 1):S11-61.
    1. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
    1. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-20.
    1. Zanchetti A, Hansson L, Clement D, Elmfeldt D, Julius S, Rosenthal T, et al. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J-shaped curve exist in smokers? J Hypertens 2003;21:797-804.
    1. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
    1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
    1. Rutter MK, Nesto RW. Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. Eur Heart J 2011;32:2247-55.
    1. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. J Hypertens 2009;27:2121-58.
    1. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884-93.
    1. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(suppl 2):B54-64.
    1. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. New Engl J Med 2010;362:1575-85.
    1. Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R, et al. Clinical outcomes in the diabetes cohort of the international verapamil SR-trandolapril study. Hypertension 2004;44:637-42.
    1. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 2005;16:2170-9.
    1. Clinical Practice Research Datalink. .
    1. Gray J, Orr D, Majeed A. Use of read codes in diabetes management in a south london primary care group: Implications for establishing disease registers. BMJ 2003;326:1130.
    1. Index of Multiple Deprivation. The English Indices of Deprivation 2004 (revised). 2007. .
    1. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-8.
    1. Hypertension in diabetes study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993;11:319-25.
    1. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: A meta-analysis in 73,913 patients. J Hypertens 2011;29:1253-69.
    1. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010;304:61-8.
    1. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the treating to new targets (TNT) trial. Eur Heart J 2010;31:2897-908.
    1. Staessen J, Bulpitt C, Clement D, De Leeuw P, Fagard R, Fletcher A, et al. Relation between mortality and treated blood pressure in elderly patients with hypertension: Report of the European working party on high blood pressure in the elderly. BMJ 1989;298:1552-6.
    1. Hollowell J. The general practice research database: Quality of morbidity data. Popul Trends 1997:36-40.
    1. Chen YC, Wu JC, Haschler I, Majeed A, Chen TJ, Wetter T. Academic impact of a public electronic health database: bibliometric analysis of studies using the general practice research database. PloS One 2011;6:e21404.

Source: PubMed

3
S'abonner